Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2016, Article ID 9639585, 7 pages
http://dx.doi.org/10.1155/2016/9639585
Case Report

Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine

1Department of Immunology, Oslo University Hospital, Montebello, 0310 Oslo, Norway
2Department of Clinical Cancer Research, Oslo University Hospital, Montebello, 0310 Oslo, Norway
3Department of Cell Therapy, Oslo University Hospital, Montebello, 0310 Oslo, Norway

Received 11 March 2016; Accepted 13 June 2016

Academic Editor: Jens Sondergaard

Copyright © 2016 Mouldy Sioud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, pp. 245–252, 1998. View at Publisher · View at Google Scholar
  2. K. Palucka and J. Banchereau, “Cancer immunotherapy via dendritic cells,” Nature Reviews Cancer, vol. 12, no. 4, pp. 265–277, 2012. View at Publisher · View at Google Scholar
  3. A. Hoos, C. M. Britten, C. Huber, and J. O'Donnell-Tormey, “A methodological framework to enhance the clinical success of cancer immunotherapy,” Nature Biotechnology, vol. 29, no. 10, pp. 867–870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Guo, M. H. Manjili, J. R. Subjeck, D. Sarkar, P. B. Fisher, and X. Y. Wang, “Therapeutic cancer vaccines: past, present and future,” Advances in Cancer Research, vol. 119, pp. 421–475, 2013. View at Publisher · View at Google Scholar
  5. R. M. Steinman, D. Hawiger, and M. C. Nussenzweig, “Tolerogenic dendritic cells,” Annual Review of Immunology, vol. 21, no. 1, pp. 685–711, 2003. View at Publisher · View at Google Scholar
  6. D. H. Munn and A. L. Mellor, “Indoleamine 2,3-dioxygenase and tumor-induced tolerance,” The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1147–1154, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Hubert, N. Jacobs, J.-H. Caberg, J. Boniver, and P. Delvenne, “The cross-talk between dendritic and regulatory T cells: good or evil?” Journal of Leukocyte Biology, vol. 82, no. 4, pp. 781–794, 2007. View at Publisher · View at Google Scholar
  8. A. L. Mellor and D. H. Munn, “Ido expression by dendritic cells: tolerance and tryptophan catabolism,” Nature Reviews Immunology, vol. 4, no. 10, pp. 762–774, 2004. View at Publisher · View at Google Scholar
  9. L. M. Francisco, P. T. Sage, and A. H. Sharpe, “The PD-1 pathway in tolerance and autoimmunity,” Immunological Reviews, vol. 236, no. 1, pp. 219–242, 2010. View at Publisher · View at Google Scholar
  10. K. L. Dennis, N. R. Blatner, F. Gounari, and K. Khazaie, “Current status of interleukin-10 and regulatory T-cells in cancer,” Current Opinion in Oncology, vol. 25, no. 6, pp. 637–645, 2013. View at Publisher · View at Google Scholar
  11. P. Hwu, M. X. Du, R. Lapointe, M. Do, M. W. Taylor, and H. A. Young, “Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation,” The Journal of Immunology, vol. 164, no. 7, pp. 3596–3599, 2000. View at Publisher · View at Google Scholar
  12. M. Wobser, H. Voigt, R. Houben et al., “Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression,” Cancer Immunology, Immunotherapy, vol. 56, no. 7, pp. 1017–1024, 2007. View at Publisher · View at Google Scholar
  13. P. Puccetti and U. Grohmann, “IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation,” Nature Reviews Immunology, vol. 7, no. 10, pp. 817–823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. G. F. Flatekval and M. Sioud, “Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase,” Immunology, vol. 128, no. 1, pp. e837–e848, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Kondo, T. Kawai, and S. Akira, “Dissecting negative regulation of Toll-like receptor signaling,” Trends in Immunology, vol. 33, no. 9, pp. 449–458, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Sioud, S. Sæbøe-Larssen, T. E. Hetland, J. Kaern, A. Mobergslien, and G. Kvalheim, “Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients,” International Journal of Oncology, vol. 43, no. 1, pp. 280–288, 2013. View at Publisher · View at Google Scholar
  17. J. S. Weber, S. O'Day, W. Urba et al., “Phase I/II study of ipilimumab for patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 26, no. 36, pp. 5950–5956, 2008. View at Publisher · View at Google Scholar
  18. L. Lee, M. Gupta, and S. Sahasranaman, “Immune Checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy,” Journal of Clinical Pharmacology, vol. 56, no. 2, pp. 157–169, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Mackiewicz, “What is new in the treatment of advanced melanoma? State of the art,” Contemporary Oncology, vol. 16, no. 5, pp. 363–370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Weber, “Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events,” The Oncologist, vol. 12, no. 7, pp. 864–872, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. D. Brown, R. L. Warren, E. A. Gibb et al., “Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival,” Genome Research, vol. 24, no. 5, pp. 743–750, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. C.-C. Chang, T. Ogino, D. W. Mullins et al., “Defective human leukocyte antigen class I-associated antigen presentation caused by a novel β2-microglobulin loss-of-function in melanoma cells,” The Journal of Biological Chemistry, vol. 281, no. 27, pp. 18763–18773, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. R. B. Holmgaard, D. Zamarin, D. H. Munn, J. D. Wolchok, and J. P. Allison, “Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4,” Journal of Experimental Medicine, vol. 210, no. 7, pp. 1389–1402, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Vacchelli, F. Aranda, A. Eggermont et al., “Trial watch: IDO inhibitors in cancer therapy,” OncoImmunology, vol. 3, no. 10, Article ID e957994, 2014. View at Publisher · View at Google Scholar · View at Scopus